2020 Pediatric Rheumatology Symposium

April 29-May 2, 2020

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 118

Long-Term Outcomes in Children Born to Anti-Ro and/or anti-La Positive Mothers
Abstract Number: 149

Low C4 Copy Number of Total C4 Gene, C4B Gene and C4BL Gene in Children with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)
Abstract Number: 137

Measuring Decision Conflict in Parents of Children with Juvenile Idiopathic Arthritis When Making the Decision to Begin Disease Modifying Anti-Rheumatic Drugs or Biologic Agents
Abstract Number: 096

Medication Adherence in Adolescents and Young Adults with Childhood Onset SLE
Abstract Number: 036

Medication Related Decision-Making in Parents of Children with Juvenile Idiopathic Arthritis
Abstract Number: 156

Metabolic Profiling in Juvenile Dermatomyositis
Abstract Number: 162

Minor Biomarkers in Juvenile Idiopathic Arthritis (JIA)
Abstract Number: 020

Murine Roseolovirus Induces Autoimmune Disease and Development of Autoantibodies
Abstract Number: 063

Musculoskeletal Ultrasound Assessment in Pediatric Knee Hypermobility
Abstract Number: 114

Musculoskeletal Ultrasound Study in Childhood Arthritis: A Limited Examination
Abstract Number: 017

MyD88 S209R-Mediated Immune Dysregulation in Mouse Models of Arthritis
Abstract Number: 021

Myositis Autoantibodies in a Racially Diverse Population of Children with Idiopathic Inflammatory Myopathies
Abstract Number: 044

Nailing Down Nailfold Capillaroscopy Practices: A Survey of Pediatric Rheumatologists Within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Network
Abstract Number: 052

Nasopharyngeal Pneumococcus Colonization in Patients with Childhood Onset Systemic Lupus Erythematosus (cSLE) Compared to Healthy Controls
Abstract Number: 046

Near Infrared Indocyanine Green Imaging Reveals Altered Anatomy and Diminished Function in Lymphatic Vessels in the Hands of Rheumatoid Arthritis Patients During Flare

« Previous Page
1
…
6
7
8
9
10
…
13
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].